Stocktoria
Black Diamond Therapeutics, Inc. BDTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-01-30
Black Diamond Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 17.9% | — | — | — | — |
| Net margin | 32.0% | — | — | — | — |
| Return on assets | 15.6% | -56.8% | -52.0% | -58.3% | -50.7% |
| Return on equity | 19.9% | -83.7% | -70.6% | -78.8% | -64.1% |
| Current ratio | 8.42 | 4.92 | 6.82 | 8.37 | 9.12 |
Source: SEC EDGAR filings · CIK 0001701541 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.